ClinicalTrials.gg
Active, not recruitingNCT06053814Updated Jun 16, 2026

NS-050/NCNP-03 in Boys With DMD (Meteor50)

A Phase 1/2 interventional study of NS-050/NCNP-03 and Placebo in Duchenne Muscular Dystrophy, sponsored by NS Pharma, Inc.. Active, not recruiting at 19 sites in 5 countries. Open to male participants aged 4 Years to 15 Years. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by NS Pharma, Inc. · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
4 Years to 15 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Muscular Dystrophy, Duchenne by NS Pharma, Inc. — 1 open to participants now, 5 under way, 1 of them phase 3. Muscular Dystrophy, Duchenne · NS Pharma, Inc..

Started
2024
with 1 other
Phase 1/2
Only one
of the 10
Registered
9th of 10
by date

Among the 10 studies in Muscular Dystrophy, Duchenne by NS Pharma, Inc., this one is one of 2 that started in 2024, is the only one in phase 1/2, and was the 9th registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

1 of the 10 studies in Muscular Dystrophy, Duchenne by NS Pharma, Inc. is open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.

This study: 4 Years to 15 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Muscular Dystrophy, Duchenne by NS Pharma, Inc., or all of them as a file.
02

Study summary

This is a Phase 1/2 study of Multiple-Ascending Dose (MAD) levels for 12 weeks of treatment followed by 24 weeks of open-label treatment with a selected dose of NS-050/NCNP-03 administered once weekly to ambulant boys with DMD, who have a DMD exon deletion amenable to exon 50 skipping.

03

Conditions studied

  • Duchenne Muscular Dystrophy
04

Who can participate

Ages eligible
4 Years to 15 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male ≥ 4 years and \<16 years of age;
  • Confirmed DMD exon deletion in the dystrophin gene that is amenable to skipping of exon 50 to restore the dystrophin mRNA reading frame;
  • Able to walk independently without assistive devices;
  • Able to complete the TTSTAND without assistance in \<20 seconds;
  • Stable dose of for at least 3 months and the dose is expected to remain on a stable dose for the duration of the study.

Other inclusion criteria may apply.

Exclusion criteria

Exclusion Criteria:

  • Evidence of symptomatic cardiomyopathy;
  • Current or previous treatment with anabolic steroids (e.g., oxendolone, oxandrolone) or products containing resveratrol or adenosine triphosphate within 3 months prior to first dose of study drug;
  • Currently taking another drug or has taken another investigational drug within 3 months prior to the first dose of study drug;
  • Surgery within the 3 months prior to the first dose of study drug or planned during the study duration;
  • Having taken any gene therapy.

Other exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Part 1: NS-050/NCNP-03

    Participants will be randomized and receive NS-050/NCNP-03 intravenous (IV) infusions once weekly for 2 weeks at each of MAD levels (1.95, 5, 10, 20, 40, and 80 mg/kg).

    Drug: NS-050/NCNP-03

  • Placebo comparator
    Part 1: Placebo

    Participants will be randomized and receive NS-050/NCNP-03 placebo-matching IV infusions once weekly for 2 weeks at each of MAD levels.

    Drug: Placebo

  • Experimental
    Part 2: NS-050/NCNP-03

    Participants will receive NS-050/NCNP-03 IV infusions once weekly for 24 weeks at the dosage selected by the Data and Safety Monitoring Board (DSMB) at the conclusion of Part 1.

    Drug: NS-050/NCNP-03

Interventions

  • DrugNS-050/NCNP-03

    NS-050/NCNP-03 solution for IV infusion.

  • DrugPlacebo

    NS-050/NCNP-03 placebo-matching solution for IV infusion.

06

What researchers measure

Primary outcomes

  1. Part 1: Overall Summary of Treatment-emergent Adverse Events (TEAEs)

    TEAEs will be summarized both at the patient level for number of TEAEs, highest severity, relationship, action, and outcome, and at the TEAE level (summarizing events) by system organ class (SOC) and preferred term (PT) as well as severity, relationship, action, and outcome. The most recent version of the Medical Dictionary for Regulatory Activities (MedDRA) will be used for coding TEAEs.

    Time frame: Baseline up to Week 24

  2. Part 1: Area Under the Plasma Concentration Versus Time Curve (AUC) of NS-050/NCNP-03

    Blood samples will be collected at the designated time frame. Pharmacokinetic (PK) parameters of NS-050/NCNP-03 will be calculated using non-compartmental methods.

    Time frame: Day 1 (1st dose) for each dose level

  3. Part 1: Amount of Drug Excreted in Urine of NS-050/NCNP-03

    Urine samples will be collected at the designated time frame. PK parameters of NS-050/NCNP-03 will be calculated using non-compartmental methods.

    Time frame: Day 1 (1st dose) for each dose level

  4. Part 2: Change from baseline in skeletal muscle dystrophin protein by immunoblot (Western blot)

    Time frame: Baseline, Week25

Secondary outcomes

  1. Part 2: Change from baseline in skeletal muscle dystrophin protein by mass spectrometry

    Time frame: Baseline, Week25

  2. Part 2: Change from baseline in skeletal muscle dystrophin protein levels by immunofluorescence staining

    Time frame: Baseline, Week25

  3. Part 2: Change from baseline in percentage of exon 50-skipped mRNA of skeletal muscle dystrophin

    Time frame: Baseline, Week25

  4. Part 2: North Star Ambulatory Assessment (NSAA) score

    The NSAA is a functional scale devised for use in ambulant children with Duchenne muscular dystrophy (DMD). It consists of 17 activities graded 0 (unable to perform), 1 (performs with modifications), 2 (normal movement). It assesses abilities necessary to remain ambulant that have been found to progressively deteriorate in untreated DMD patients, as well as in other muscular dystrophies such as Becker Muscular Dystrophy. NSAA Total Score ranges from 0 to 34, with a score of 34 implying normal function.

    Time frame: Baseline, Week13, Week25

  5. Part 2: Time to Stand (TTSTAND)

    Time frame: Baseline, Week13, Week25

  6. Part 2: Time to Run/Walk 10 Meters (TTRW)

    Time frame: Baseline, Week13, Week25

  7. Part 2: Time to Climb 4 Stairs (TTCLIMB)

    Time frame: Baseline, Week13, Week25

  8. Part 2: Total distance of 6 Minute Walk Test (6MWT)

    Time frame: Baseline, Week13, Week25

  9. Part 2: Muscle strength measured by Quantitative Muscle Testing (QMT)

    Time frame: Baseline, Week13, Week25

  10. Part 2: Grip/Pinch Strength

    Time frame: Baseline, Week13, Week25

  11. Part 2: Performance of Upper Limb (PUL) 2.0. score

    The PUL 2.0 provides both a total score and sub-scores for the 3 domains (shoulder, middle, and distal) that in DMD are progressively involved with a proximal to distal gradient. The PUL includes 22 items with an entry item to define the starting functional level. The 22 items are subdivided into the high level shoulder dimension (6 items), middle level elbow dimension (9 items), and distal wrist and hand dimension (7 items). For weaker patients, a low score on the entry item (0 2) means high level items do not need to be performed. Scoring options vary across the scale between 0-1 and 0-2 according to performance. Each dimension can be scored separately with a maximum score of 12 for the high level shoulder dimension, 17 for the middle level elbow dimension, and 13 for the distal wrist and hand dimension. A total score can be achieved by adding the 3 level scores (maximum total score of 42).

    Time frame: Baseline, Week13, Week25

07

Study locations

19 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Mar 2028, 42 months after the start.

Of 23 phase 1/2 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 63. This study's planned 42 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2023
First posted
Sep 26, 2023
StartActual
Sep 18, 2024
Primary completionEst.
Mar 2028
CompletionEst.
Mar 2028
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06053814
Lead sponsor
NS Pharma, Inc.
Collaborators
Nippon Shinyaku Co., Ltd.
Responsible party
Sponsor
First posted
Sep 26, 2023
Start date
Sep 18, 2024
Primary completion
Mar 2028 (estimated)
Completion
Mar 2028 (estimated)
Last update
Jun 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion